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Background
Inactive HBV carriers, under immunosuppressive treat-
ment for malignancies or rheumatologic diseases, have
an increased risk for HBV reactivation. HBV reactivation
under immunosuppression has a high rate of acute liver
failure and death. HBV screening is mandatory for
patients with hematological malignancies or rheumatolo-
gic diseases who are due to receive immunosuppressive
treatment.
Methods
We retrospectively analyzed 13 patients from Depart-
ment 3 of the National Institute for Infectious Diseases
“Prof. Dr. Matei Balş” that were diagnosed with HBV
reactivation under immunosuppressive treatment for dif-
ferent malignancies or rheumatologic diseases.
Results
Thirteen patients were enrolled, 6 women and 7 men,
with a median age of 56 years [32-70.5]. Seven patients
were diagnosed with hematologic malignancies (6 with
non-Hodgkin lymphoma and 1 with chronic lymphatic
leukemia), 4 with rheumatologic diseases (1 with anky-
losing spondylitis, 1 with Reiter syndrome and 2 with
rheumatoid polyarthritis), 1 patient with ovarian cancer
and 1 patient with renal transplant. Of 13 patients, one
had negative HBsAg and protective HBs antibodies
titers, before immunosuppressive treatment, with further
HBs retroseroconversion.
On admission, TGP median value was 1,125 IU/dL
[491-1738]. Median prothrombin concentration on
admission was 85% [68-101] and median nadir of pro-
thrombin concentration was 66% [54-84].
Median hospitalization period was 20.77 days. Hospita-
lization period was directly correlated with ALT and AST
values at the time of admission (p = 0.06 respectively p =
0.015) and negatively correlated with prothrombin con-
centration at admission (p = 0.059) and lymphocytes
number (p = 0.058).
Ten patients were treated with entecavir and three with
lamivudine. Three patients died, all of them with hemato-
logic malignancies – two deaths were due to hematologic
disease and one due to liver failure. Median age of
deceased patients was 73 years [68.0-75.0], while in the
surviving group the median age was 50 years [27.7-58.5]
(p = 0.049).
Conclusion
In HBV reactivation patients, older age is a risk factor
for mortality. Higher liver transaminases and lower pro-
thrombin concentration and lymphocytes are associated
with longer hospitalization period. Even patients with
negative HBs antigen can reactivate HBV infection dur-
ing immunosuppression, requiring close monitoring.
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